ORPHA:206436
Infantile Krabbe disease
Also known as: Krabbe disease, classic form · Krabbe disease, early-onset
Publications
215
60.4th percentile
Trials
2
Interventional, condition-specific
Researchers
977
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016089
- UMLS:C0751273
Additional Mondo synonyms (5)
early onset Krabbe disease · early symptomatic Krabbe disease · early-onset Krabbe disease · infantile onset Krabbe disease · infantile-onset Krabbe disease
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
215 matched papers (127 in last 10 years) Source
- Phenotype characterisedPresent
71 HPO annotations (e.g. Irritability; Unexplained fevers; Sensorimotor neuropathy) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
71
Associated phenotypes · MONDO:0016089
- Irritability
- Unexplained fevers
- Sensorimotor neuropathy
- Inappropriate crying
- Psychomotor deterioration
Showing 5 of 71 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
215
215 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
215 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
127 in the last 10 years · high confidence · 60.4th percentile (publications denominator)
Phrase hits: 215 · MeSH hits: 0
Who's working on it?
977
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Escolar ML20 papers · 2024
Program for the Study of Neurodevelopment in Rare Disorders, Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, 4401 Penn Avenue, Pittsburgh, PA, 15224, USA. Maria.Escolar@chp.edu.
Papers in Europe PMC - 02Gelb MH12 papers · 2021
Department of Chemistry, Biochemistry, and gelb@chem.washington.edu.
Papers in Europe PMC - 03Wenger DA12 papers · 2021
Department of Neurology, Jefferson Medical College, Philadelphia, Pennsylvanian, USA.
Papers in Europe PMC - 04Kurtzberg J11 papers · 2026
Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
Papers in Europe PMC - 05Orsini JJ11 papers · 2026
New York State Department of Health, Wadsworth Center, Albany, NY 12201-0509, United States. jjo01@health.state.ny.us
Papers in Europe PMC - 06Matern D10 papers · 2026
Biochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Papers in Europe PMC - 07Poe MD10 papers · 2024
Program for the Study of Neurodevelopment in Rare Disorders, Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, 4401 Penn Avenue, Pittsburgh, PA, 15224, USA.
Papers in Europe PMC - 08Bongarzone ER7 papers · 2021
Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Papers in Europe PMC - 09Luzi P6 papers · 2021
Departments of Medicine and Biochemstry and Molecular Biology, Thomas Jefferson University, Phildelphia, Pennsylvania, USA.
Papers in Europe PMC - 10Rafi MA6 papers · 2021
Department of Medicine (Medical Genetics), Jefferson Medical College, Philadelphia, PA 19107, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; none in our sample are currently recruiting. 4 trials are registered for Krabbe disease, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
high confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: Krabbe disease
4
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 24 · after dedupe 24 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 24 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (24)
- ctis·2023-504900-28-00·11·A Phase 1/2 Clinical Study of Intravenous Gene Transfer with an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE)
skipped — LLM skipped (--skip-llm)
- ctis·2025-522275-28-00·Authorised·Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program
skipped — LLM skipped (--skip-llm)
- ctis·2025-524062-16-00·Authorised·A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder
skipped — LLM skipped (--skip-llm)
- ctis·2025-520842-31-00·Authorised·ANTIPROM - Comparison of two prophylactic antibiotic regimens in case of preterm prelabor rupture of membranes before 34 weeks of gestation: a randomized controlled trial
skipped — LLM skipped (--skip-llm)
- ctis·2025-523711-11-00·Authorised, ongoing·A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523284-37-00·Authorised, ongoing·CHARACTERIZATION OF ASTROCYTE REACTIVITY WITH [18F]F-DED PET IN NEURODEGENERATIVE DISEASES
skipped — LLM skipped (--skip-llm)
- ctis·2022-503070-36-00·Authorised, ongoing·C1091009 - A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS
skipped — LLM skipped (--skip-llm)
- ctis·2024-515598-82-00·Authorised, recruiting·A Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy
skipped — LLM skipped (--skip-llm)
- ctis·2024-517187-36-01·Authorised, recruiting·A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer’s Disease
skipped — LLM skipped (--skip-llm)
- ctis·2024-519853-12-00·Authorised, ongoing·Statin Intervention for Severe Early-Onset Placental Insufficiency: A Randomized Controlled Trial Assessing daily
Administration as a Treatment Strategy (STATIN-PRE trial)
skipped — LLM skipped (--skip-llm)
- ctis·2024-518564-12-00·Authorised, ongoing·Antibiotic pharmacokinetics in women with twin pregnancy
skipped — LLM skipped (--skip-llm)
- ctis·2024-519778-38-00·Authorised, recruiting·Cognitive effects of adjuntive Vortioxetine in early Schizophrenia
skipped — LLM skipped (--skip-llm)
- ctis·2023-509341-12-00·Authorised, ongoing·AN OPEN LABEL, RANDOMISED, CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY OF ENDOBRONCHIAL ADMINISTRATION OF ALLOGENEIC MESENCHYMAL STROMAL CELLS IN PATIENTS WITH LUNG TRANSPLANT CHRONIC REJECTION: Study ENDOSC-CLAD
skipped — LLM skipped (--skip-llm)
- ctis·2024-518086-99-00·Cancelled·Young adults with early-onset obesity treated with semaglutide
-The RESETTLE study
- a randomized double blind placebo-controlled clinical trial
skipped — LLM skipped (--skip-llm)
- ctis·2024-513457-70-00·Cancelled·A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, with Open Label Extension, in Patients with Treatment Resistant Depression
skipped — LLM skipped (--skip-llm)
- ctis·2024-515356-21-00·Cancelled·GFM-EPO-PRETAR: A randomized trial testing early versus late onset of EPO alfa treatment in lower risk MDS with non RBC transfusion dependent anemia and without del 5q
skipped — LLM skipped (--skip-llm)
- ctis·2023-504840-32-00·Expired·A Randomized, Double-blind, Placebo-controlled, Global Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)
skipped — LLM skipped (--skip-llm)
- ctis·2024-515198-91-00·Expired·A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer’s Disease (DIAD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-511970-66-00·Cancelled·A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA, for the treatment of early onset Metachromatic Leukodystrophy (MLD)
skipped — LLM skipped (--skip-llm)
- ctis·2023-506359-68-00·Expired·A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis
skipped — LLM skipped (--skip-llm)
- ctis·2023-508363-79-00·Authorised, ongoing·A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD
skipped — LLM skipped (--skip-llm)
- ctis·2023-503705-10-00·Authorised, ongoing·Patient- and care-related benefits of amyloid PET imaging (ENABLE)
skipped — LLM skipped (--skip-llm)
- ctis·2022-500691-59-00·Cancelled·A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease
skipped — LLM skipped (--skip-llm)
- ctis·2022-500367-12-00·Authorised, recruiting·A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Infantile Krabbe disease — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Infantile Krabbe disease" OR "Krabbe disease, classic form" OR "Krabbe disease, early-onset" OR "early onset Krabbe disease" OR "early symptomatic Krabbe disease" OR "early-onset Krabbe disease" OR "infantile onset Krabbe disease" OR "infantile-onset Krabbe disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Infantile Krabbe disease" OR "Krabbe disease, classic form" OR "Krabbe disease, early-onset" OR "early onset Krabbe disease" OR "early symptomatic Krabbe disease" OR "early-onset Krabbe disease" OR "infantile onset Krabbe disease" OR "infantile-onset Krabbe disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"Krabbe disease"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:16:41.837Z
